Drug Approval | April 28, 2024
Zydus receives final approval from USFDA for Tretinoin Cream
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
New solvent-free micronization technology expanded at the Darmstadt site in Germany
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
The proposed facility is expected to be operational around January, 2027
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Subscribe To Our Newsletter & Stay Updated
